Skip to main content
SpringerLink
Log in

Multi-gene panel testing for hereditary cancer susceptibility in a rural Familial Cancer Program

  • Original Article
  • Published:
Familial Cancer Aims and scope Submit manuscript

Abstract

This study explores our Familial Cancer Program’s experience implementing multi-gene panel testing in a largely rural patient population. We conducted a retrospective review of patients undergoing panel testing between May 2011 and August 2015. Our goal was to evaluate factors that might be predictors of identifying variants (pathogenic or uncertain significance) and to assess clinical management changes due to testing. We utilized a structured family history tool to determine the significance of patient’s family histories with respect to identification of genetic variants. A total of 227 patients underwent panel testing at our center and 67 patients (29.5 %) had variants identified, with 8 (3.5 %) having multiple variants. Overall, 44 patients (19.4 %) had a variant of uncertain significance (VUS) and 28 patients (12.3 %) had a pathogenic variant detected, with 10 (4.4 %) having pathogenic variants in highly penetrant genes. We found no statistical difference in patient familial and personal cancer history, age, rural status, Ashkenazi Jewish ancestry, insurance coverage and prior single-gene testing among those with pathogenic, VUS and negative panel testing results. There were no predictors of pathogenic variants on regression analysis. Panel testing changed cancer screening and management guidelines from that expected based on family history alone in 13.2 % of patients. Ultimately, cancer panel testing does yield critical information not identified by traditional single gene testing but maximal utility through a broad range of personal and family histories requires improved interpretation of variants.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Blazer KR, Nehoray B, Solomon I et al (2015) Next-generation testing for cancer risk: perceptions, experiences, and needs among early adopters in community healthcare settings. Genet Test Mol Biomarkers 19:657–665

    Article  PubMed  PubMed Central  Google Scholar 

  2. Hiraki S, Rinella ES, Schnabel F, Oratz R, Ostrer H (2014) Cancer risk assessment using genetic panel testing: considerations for clinical application. J Genet Couns 23:604–617

    Article  PubMed  Google Scholar 

  3. Susswein LR, Marshall ML, Nusbaum R et al (2015) Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. Genet Med. doi:10.1038/gim.2015.166

  4. Desmond A, Kurian AW, Gabree M et al (2015) Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment. JAMA Oncol 1:943–951

    Article  PubMed  Google Scholar 

  5. Slavin TP, Niell-Swiller M, Solomon I et al (2015) Clinical application of multigene panels: challenges of next-generation counseling and cancer risk management. Front Oncol 5:208. doi:10.3389/fonc.2015.00208

    PubMed  PubMed Central  Google Scholar 

  6. LaDuca H, Stuenkel AJ, Dolinsky JS et al (2014) Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Genet Med 16:830–837

    Article  PubMed  PubMed Central  Google Scholar 

  7. Selkirk CG, Vogel KJ, Newlin AC et al (2014) Cancer genetic testing panels for inherited cancer susceptibility: the clinical experience of a large adult genetics practice. Fam Cancer 13:527–536

    Article  CAS  PubMed  Google Scholar 

  8. Greenblatt MS (2015) Sequence variants of uncertain significance: what to do when genetic test results are not definitive. Surg Oncol Clin N Am 24(4):833–846. doi:10.1016/j.soc.2015.06.009

    Article  PubMed  Google Scholar 

  9. Vallée MP, Francy TC, Judkins MK, Babikyan D, Lesueur F, Gammon A, Goldgar DE, Couch FJ, Tavtigian SV (2012) Classification of missense substitutions in the BRCA genes: a database dedicated to Ex UVs. Hum Mutat 33:22–28. doi:10.1002/humu.21629

    Article  PubMed  Google Scholar 

  10. McClain MR et al (2005) An evaluation of BRCA1 and BRCA2 founder mutations penetrance estimates for breast cancer among Ashkenazi Jewish women. Genet Med 7(1):34–39

    Article  CAS  PubMed  Google Scholar 

  11. Frey MK, Kim SH, Bassett RY et al (2015) Rescreening for genetic mutations using multi-gene panel testing in patients who previously underwent non-informative genetic screening. Gynecol Oncol 139:211–215

    Article  PubMed  Google Scholar 

  12. Kurian AW, Hare EE, Mills MA et al (2014) Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol 32:2001–2009

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Yorczyk A, Robinson LS, Ross TS (2015) Use of panel tests in place of single gene tests in the cancer genetics clinic. Clin Genet 88:278–282

    Article  CAS  PubMed  Google Scholar 

  14. Robson M (2014) Multigene panel testing: planning the next generation of research studies in clinical cancer genetics. J Clin Oncol 32:1987–1989

    Article  CAS  PubMed  Google Scholar 

  15. Cragun D, Radford C, Dolinsky JS, Caldwell M, Chao E, Pal T (2014) Panel-based testing for inherited colorectal cancer: a descriptive study of clinical testing performed by a US laboratory. Clin Genet 86:510–520

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Pilgrim SM, Pain SJ, Tischkowitz MD (2014) Opportunities and challenges of next-generation DNA sequencing for breast units. Br J Surg 101:889–898

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine and University of Vermont Cancer Center, University of Vermont College of Medicine, 89 Beaumont Ave, Given E214, Burlington, VT, 05405, USA

    David J. Hermel, Wendy C. McKinnon, Marie E. Wood & Marc S. Greenblatt

Authors
  1. David J. Hermel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wendy C. McKinnon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marie E. Wood
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marc S. Greenblatt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marc S. Greenblatt.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hermel, D.J., McKinnon, W.C., Wood, M.E. et al. Multi-gene panel testing for hereditary cancer susceptibility in a rural Familial Cancer Program. Familial Cancer 16, 159–166 (2017). https://doi.org/10.1007/s10689-016-9913-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10689-016-9913-5

Keywords

Search

Navigation